The impact of axillary lymph node dissection on the indication of adjuvant abemaciclib in high-risk hormone receptor-positive breast cancer: real-world analysis from a multicenter cohort in Brazil
Introduction: Adjuvant abemaciclib combined with endocrine therapy improves outcomes in patients with high-risk, hormone receptor-positive (HR+)/human epidermal growth factor receptor 2 (HER2)-negative early breast cancer. Lymph node involvement is a key determinant of recurrence risk and treatment decisions. However,...